Form 8-K - Current report:
SEC Accession No. 0001213900-25-122777
Filing Date
2025-12-17
Accepted
2025-12-17 16:01:35
Documents
12
Period of Report
2025-12-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0270035-8k_neuphoria.htm   iXBRL 8-K 35271
  Complete submission text file 0001213900-25-122777.txt   199393

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE neup-20251212.xsd EX-101.SCH 3023
3 XBRL LABEL FILE neup-20251212_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE neup-20251212_pre.xml EX-101.PRE 22364
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0270035-8k_neuphoria_htm.xml XML 3569
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41157 | Film No.: 251579165
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)